NCT07015268 - A Clinical Study of KLH-2109 in Patients With Endometriosis | Biotech Hunter

Enrollment

288

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions

Endometriosis

Interventions

DRUG

KLH-2109

"\- KLH-2109 tablet: Oral administration~\- Leuprorelin acetate placebo: Subcutaneous administration"

DRUG

Leuprorelin acetate

"\- KLH-2109 placebo tablet: Oral administration~\- Leuprorelin acetate: Subcutaneous administration"

Trial Locations (1)

RECRUITING

Research Site, Multiple Locations